Evotec has been granted a patent for ophthalmic formulations containing aflibercept, designed for treating eye disorders through intravitreal or topical administration. The formulation includes specific concentrations of histidine buffer, non-ionic surfactants, tonicifying agents, and stabilizing amino acids, with a targeted pH and osmolality. GlobalData’s report on Evotec gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Evotec, NSAID cancer drugs was a key innovation area identified from patents. Evotec's grant share as of June 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Ophthalmic formulation containing aflibercept for eye disorders
The granted patent US12005097B2 outlines a novel ophthalmic formulation designed for the treatment of various eye disorders. The formulation includes aflibercept at concentrations ranging from 5 to 100 mg/mL, combined with a histidine buffer (5-50 mM), and a non-ionic surfactant selected from several options, including polysorbate and poloxamer, at concentrations between 0.001% to 5% (w/v). Additionally, the formulation incorporates a tonicifying agent, which can be a polyol or an amino acid, at a concentration of 2-4% (w/v), ensuring a final osmolality of 300±50 mOsm/kg. The pH of the formulation is maintained between 5.0 and 6.5, with specific claims detailing variations in the concentration of the histidine buffer, the type of non-ionic surfactant, and the choice of tonicifying agents.
Furthermore, the patent describes a method for treating eye disorders through the intravitreal injection of this formulation. The targeted conditions include macular edema following retinal vein occlusion, diabetic macular edema, and neovascular age-related macular degeneration, among others. Specific claims highlight the formulation's effectiveness against particular disorders, such as macular edema due to retinal vein occlusion and various forms of age-related macular degeneration. The patent emphasizes the therapeutic potential of the formulation, which combines specific ingredients and concentrations to optimize treatment outcomes for patients suffering from these eye conditions.
To know more about GlobalData’s detailed insights on Evotec, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
